{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:53:08Z","timestamp":1793533988278,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.yebeh.2023.109464","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T13:21:17Z","timestamp":1697203277000},"page":"109464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus"],"prefix":"10.1016","volume":"148","author":[{"given":"Chiara","family":"Martellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Atanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Attardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cascino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Pardeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppa","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Roberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Morace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8827-7324","authenticated-orcid":false,"given":"Angelo","family":"Labate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2023.109464_b0005","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.2147\/IJGM.S295855","article-title":"Epidemiology and outcomes of status epilepticus","volume":"14","author":"Ascoli","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.yebeh.2023.109464_b0010","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus \u2013 report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109464_b0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2023.109464_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14656566.2018.1541349","article-title":"Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy","volume":"20","author":"Morano","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2023.109464_b0025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/14737175.2021.1862649","article-title":"Management of status epilepticus in patients with liver or kidney disease: a narrative review","volume":"21","author":"Mastroianni","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2023.109464_b0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14737175.2022.2057224","article-title":"Status epilepticus in pregnancy: a literature review and a protocol proposal","volume":"22","author":"Roberti","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2023.109464_b0035","first-page":"5719","article-title":"Brivaracetam: Review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures","volume":"9","author":"Mumoli","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.yebeh.2023.109464_b0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109464_b0045","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419873518","article-title":"Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience","volume":"12","author":"Steinhoff","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2023.109464_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109464_b0055","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-020-00747-z","article-title":"Therapeutic options for patients with refractory status epilepticus in palliative settings or with a limitation of life-sustaining therapies: a systematic review","volume":"34","author":"Willems","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2023.109464_b0060","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109464_b0065","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/epi.13787","article-title":"Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus","volume":"58","author":"Niquet","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109464_b0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1528-1167.2011.03243.x","article-title":"Rational polytherapy in the treatment of acute seizures and status epilepticus","volume":"52","author":"Wasterlain","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109464_b0075","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1212\/WNL.0b013e3181cff747","article-title":"Temporal lobe abnormalities on brain MRI in healthy volunteers: a prospective case-control study","volume":"74","author":"Labate","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109464_b0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40263-019-00652-0","article-title":"Intravenous brivaracetam in the treatment of status epilepticus: a systematic review","volume":"33","author":"Brigo","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2023.109464_b0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.seizure.2021.01.014","article-title":"Intravenous brivaracetam in status epilepticus: a multicentric retrospective study in Italy","volume":"86","author":"Orlandi","year":"2021","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023003839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023003839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:51:15Z","timestamp":1761504675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023003839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":17,"alternative-id":["S1525505023003839"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109464","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109464"}}